BioCryst Pharmaceuticals | 营业费用



金融业
股票价格
USD
资产
USD 446.42M
现金及等价物
USD 84.08M
销售成本
USD 12.27M
流动资产
USD 355.68M
流动负债
USD 190.24M
债务
USD 828.6M
股息收益率
0
EBIT
USD -4.51M
EBITDA
USD -20.3M
员工
536
EPS每股收益
USD -0.13
股本和储备
USD -387.89M
销售毛利
USD -88.88M
债务利息支出
USD 24.45M
利息收入
USD -0.13
贷款资金
USD 194.37M
市值
USD 1.8B
净收入
USD -88.88M
营业费用
USD -387.89M
营业利润
USD -2.54M
普通股股本
USD 1.9M
PE价格收益
1.08K
税前利润
USD -86.95M
销售收入
USD -86.95M
销售和管理费用
USD 80.47M
股票
USD 5.23M
贸易债权人
USD 5.57M
应收帐款人
USD 79.07M


营业费用 更改 日
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Chugai Pharma JPY 177.3B 604M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
DBV Technologies USD 37.05M 4.06M 2025-09
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Glaxosmithkline GBP 7.77B 2.22B 2025-09
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novavax USD 218.53M 34.86M 2024-09
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12


BioCryst Pharmaceuticals 营业费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Mar 2026.